There are currently 54 active clinical trials seeking participants for Glioma research studies. The states with the highest number of trials for Glioma participants are California, Pennsylvania, Ohio and Michigan.
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
NCT05045027
Recruiting
This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Glioma, Malignant Glioma, Recurrent Glioma, Recurrent Malignant Glioma
Register for Updates
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
NCT05979064
Recruiting
This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/19/2023
Locations: Lenox Hill Brain Tumor Center, New York, New York
Conditions: Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, GBM, Brain Cancer, High Grade Glioma
Register for Updates
Registering Genomics and Imaging of Tumors (ReGIT)
NCT05386043
Recruiting
This study is investigating how brain tumors might mutate over time, and whether new brain imaging tools like MRI and PET can predict these mutations.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/17/2023
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Glioma
Register for Updates
18F-Fluciclovine PET-MRI in High-grade Glioma
NCT05553041
Recruiting
The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes that can occur after treatment.
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
08/09/2023
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Glioma, High Grade Glioma, Glioma, Malignant, Glioma Intracranial, Diffuse Glioma
Register for Updates
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
NCT03152318
Recruiting
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: Johns Hopkins University Medical Center, Baltimore, Maryland +4 locations
Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
Register for Updates
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
NCT02372409
Recruiting
By employing a combination of advanced MRI techniques and correlative serum biomarkers of blood brain barrier (BBB) disruption, the investigators plan to develop a powerful, first of its kind clinical algorithm in pediatrics whereby the investigators can measure and identify the window of maximal BBB disruption post MLA to 1) allow for an alternative to surgery in incompletely resected tumors, 2) allow for optimal chemotherapeutic dosing to achieve the greatest benefits and the least systemic si... Read More
Gender:
All
Ages:
Between 3 years and 21 years
Trial Updated:
01/29/2023
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
Register for Updates